Clinical trial
Tolerability of Grazax-R in Children
NCT00298701 · ALK-Abelló A/S, Industry · Completed
Key facts
| NCT number | NCT00298701 |
|---|---|
| Title | Tolerability of Grazax-R in Children |
| Official title | A Randomised, Double-Blind, Placebo-Controlled, Multi-Centre Phase I Trial Investigating the Safety of GRAZAX-R in Children Aged 5-12 Years With Grass Pollen Induced Rhinoconjunctivitis (With/Without Asthma) |
| Lead sponsor | ALK-Abelló A/S, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Allergy |
| Intervention type | Biological |
| Interventions | ALK Grass tablet |
| Enrollment | 50 |
| Start date | Feb 1, 2006 |
| Completion | Apr 1, 2006 |
| First posted | Mar 3, 2006 |
| Last update posted | May 4, 2006 |
| Countries | Germany |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: